Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025

Overcoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate.

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJingyi ZhangZZZhenwei ZhangJLJinghua Liu

Discussion

Loading...

Member takes

Overview

Research reveals a novel artemisinin conjugate that boosts NOXA production, overcoming drug resistance in acute myeloid leukemia.

Key Points

  • A1 conjugate significantly enhances NOXA production, enabling effective degradation of Mcl-1 and cyclin D1 proteins.
  • Clinical efficacy of venetoclax in treating acute myeloid leukemia is limited by Mcl-1 and Bcl-xL protein overexpression.
  • This study employed a chemical synthesis approach to create a novel conjugate that improves the activity of venetoclax.
  • Therapeutic strategies using this generation of compounds may help overcome drug resistance in AML treatment.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/689fc957e46e096235ce1981https://doi.org/10.1182/bloodadvances.2025015806
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies2025 · 9 citations
  2. 2Factors affecting response and resistance to venetoclax in acute myeloid leukemia2025 · 6 citations
  3. 3TP53 activation by the natural quassinoid brusatol enhances venetoclax efficacy and overcomes resistance in myeloid leukemias2025
  4. 4[Establishment and Mechanistic Study of Venetoclax-Resistant Cell Lines in Acute Myeloid Leukemia].2025
  5. 5Inhibition of <scp>CDK</scp>9 enhances <scp>AML</scp> cell death induced by combined venetoclax and azacitidine2025 · 1 citations